INS and Hypoglycemia: The insulinotropic effect of DPP-4 inhibitors explains the phenomenon that this class increasingly is replacing the use of sulfonylureas as insulin releasing agents; especially since the intrinsic hypoglycaemia risk of DPP-4 inhibitors is very low.